Stockscreener 앱 받기
26.90
9.85%
-2.94
시장 영업 전:
26.70
-0.20
-0.74%
전일 마감가:
$29.84
열려 있는:
$30.221
하루 거래량:
2.53M
Relative Volume:
1.02
시가총액:
$4.29B
수익:
$295.41M
순이익/손실:
$-49.64M
주가수익비율:
-82.16
EPS:
-0.3274
순현금흐름:
$-29.54M
1주 성능:
-6.50%
1개월 성능:
+10.79%
6개월 성능:
+91.05%
1년 성능:
+85.90%
1일 변동 폭
$26.85
$30.74
1주일 범위
$26.85
$30.74
52주 변동 폭
$12.00
$30.74
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
명칭
Adaptive Biotechnologies Corp
전화
206-659-0067
주소
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT vs TMO, DHR, NTRA, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
26.90 | 4.70B | 295.41M | -49.64M | -29.54M | -0.3274 |
TMO
Thermo Fisher Scientific Inc
|
656.58 | 241.26B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
215.61 | 150.48B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
400.65 | 59.47B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
169.33 | 48.71B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
436.43 | 42.59B | 3.77B | 449.25M | 240.68M | 7.8556 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-02 | 재개 | Morgan Stanley | Equal-Weight |
| 2025-09-30 | 개시 | Guggenheim | Buy |
| 2025-06-18 | 개시 | Craig Hallum | Buy |
| 2025-03-21 | 업그레이드 | Goldman | Neutral → Buy |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-12-21 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-08-25 | 개시 | Credit Suisse | Underperform |
| 2022-06-03 | 개시 | Piper Sandler | Neutral |
| 2022-02-16 | 재확인 | BTIG Research | Buy |
| 2022-02-16 | 재확인 | BofA Securities | Buy |
| 2022-02-16 | 재확인 | Goldman | Neutral |
| 2022-02-16 | 재확인 | JP Morgan | Overweight |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-03-03 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-10-08 | 재개 | BTIG Research | Buy |
| 2020-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2020-06-03 | 개시 | Goldman | Buy |
| 2019-07-23 | 개시 | BTIG Research | Buy |
| 2019-07-22 | 개시 | BofA/Merrill | Buy |
| 2019-07-22 | 개시 | Cowen | Outperform |
| 2019-07-22 | 개시 | Goldman | Neutral |
| 2019-07-22 | 개시 | Guggenheim | Buy |
| 2019-07-22 | 개시 | William Blair | Outperform |
모두보기
Adaptive Biotechnologies Corp 주식(ADPT)의 최신 뉴스
Options exercised over three months will supply an officer's planned sale at Adaptive Biotechnologies (ADPT). - Stock Titan
Adaptive Biotechnologies slips as recent rally cools despite no clear new negative catalyst - Quiver Quantitative
ADPT Maintained by Guggenheim -- Price Target Raised to $32 - GuruFocus
ETFs Investing in Adaptive Biotechnologies Corp. Stocks - TradingView
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Rated "Buy" in New Coverage at The Goldman Sachs Group - MarketBeat
ADPT Initiates Coverage On Goldman Sachs -- Rating Set to Buy - GuruFocus
Adaptive Biotechnologies Corp (ADPT) Stock Down 3.1% but Still O - GuruFocus
Form 4 Adaptive Biotechnologies Corp For: 28 September By Investing.com - Investing.com South Africa
Adaptive Biotechnologies CPO Francis Lo sells $3.2 million in stock - Investing.com
Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure - Yahoo Finance
Adaptive Biotechnologies (ADPT) Jumped, So What Is Driving Attention Now? - Yahoo Finance
Adaptive Biotechnologies Corp (ADPT) Stock Up 6.0% but GF Value Says Overvalued -- GF Score: 68/100 - GuruFocus
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Up 4.4%Should You Buy? - MarketBeat
Adaptive Biotechnologies stock hits 52-week high at 28.79 USD - Investing.com
Adaptive Biotechnologies stock hits 52-week high at 28.79 USD By Investing.com - Investing.com Australia
NCCN’s Myeloma MRD Update Spotlighting clonoSEQ Could Be A Game Changer For Adaptive Biotechnologies (ADPT) - Yahoo Finance
Adaptive Biotechnologies (ADPT) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Adaptive Biotechnologies (ADPT): Can Blood Cancer Guidelines Boost Repeat Testing? - Insider Monkey
Adaptive Biotechnologies (NASDAQ:ADPT) Price Target Raised to $34.00 at BTIG Research - MarketBeat
Adaptive Biotechnologies (NASDAQ:ADPT) Reaches New 1-Year HighShould You Buy? - MarketBeat
Bank of America Corp DE Makes New Investment in Adaptive Biotechnologies Corporation $ADPT - MarketBeat
Tidal Investments LLC Takes $855,000 Position in Adaptive Biotechnologies Corporation $ADPT - MarketBeat
Adaptive Biotechnologies CPO Francis Lo sells $3.2m in stock By Investing.com - Investing.com Australia
Adaptive Biotechnologies CPO Francis Lo sells $3.2m in stock - Investing.com
Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells 115,406 Shares - MarketBeat
Adaptive Biotechnologies (ADPT) HR chief sells over 100,000 shares under preset plan - Stock Titan
Adaptive Biotechnologies Corp (ADPT) Key Financial Ratios – Valuation, Profitability & More - Value Research
Adaptive biotechnologies chief commercial officer sells $32,265 in shares. - Investing.com
Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells 1,195 Shares - MarketBeat
Adaptive Biotechnologies (NASDAQ: ADPT) CCO sells shares under pre-set trading plan - Stock Titan
ADPT Looks 137.6% Overvalued on GF Value™ - GuruFocus
Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ® - Yahoo Finance
Alert incorrectly tagged to Adaptive Biotechnologies withdrawn - marketscreener.com
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Adaptive Biotechnologies (ADPT) officer to sell 142K shares - Stock Titan
Adaptive Biotechnologies (NASDAQ:ADPT) Hits New 52-Week HighTime to Buy? - MarketBeat
Adaptive Biotechnologies stock hits 52-week high at 26.89 USD By Investing.com - Investing.com India
A Look at Adaptive Biotechnologies Corp (ADPT) After 7.7% Gain -- GF Value $11.66 vs Price $26.68 - GuruFocus
Officer at Adaptive Biotechnologies (NASDAQ: ADPT) plans sale of 1,195 shares - Stock Titan
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Up 6.4%What's Next? - MarketBeat
Adaptive Biotechnologies stock hits 52-week high at 26.89 USD - Investing.com
Adaptive Biotechnologies Corp (ADPT) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Legal & General Group Plc Takes $7.62 Million Position in Adaptive Biotechnologies Corporation $ADPT - MarketBeat
Adaptive Biotechnologies (NASDAQ: ADPT) director reports stock gift, still holds 66,100 shares - Stock Titan
Wellington Management Group LLP Has $126.80 Million Stake in Adaptive Biotechnologies Corporation $ADPT - MarketBeat
Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - The Manila Times
Morgan Stanley’s healthcare conference sets a biotech chat for Sept. 15 - Stock Titan
Adaptive Biotechnologies Corp (ADPT) Peer Comparison – Compare with Others - Value Research
Adaptive Biotechnologies Corp (ADPT) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Director Katey Owen Sells 9,615 Shares of Adaptive Biotechnologies Corp (ADPT) - GuruFocus
Adaptive Biotechnologies director Owen sells $249,990 in stock. By Investing.com - Investing.com India
Adaptive Biotechnologies Corp (ADPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Adaptive Biotechnologies Corp 주식 (ADPT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| LO FRANCIS | Chief People Officer |
Sep 16 '26 |
Option Exercise |
9.57 |
105,560 |
1,010,581 |
336,273 |
| LO FRANCIS | Chief People Officer |
Sep 16 '26 |
Sale |
28.06 |
115,406 |
3,238,004 |
220,867 |
| BOBULSKY SUSAN | Chief Commercial Officer, MRD |
Sep 15 '26 |
Sale |
27.00 |
1,195 |
32,265 |
395,794 |
0.99%
0.56%
자본화:
|
볼륨(24시간):